Acadia Pharmaceuticals Inc’s recently made public that its EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. unloaded Company’s shares for reported $0.15 million on Aug 19 ’24. In the deal valued at $15.28 per share,9,733 shares were sold. As a result of this transaction, Schneyer Mark C. now holds 43,735 shares worth roughly $0.64 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Teehan Brendan sold 9,534 shares, generating $145,680 in total proceeds. Upon selling the shares at $15.28, the EVP, COO, HEAD OF COMMERCIAL now owns 52,177 shares.
Before that, DAVIS STEPHEN sold 31,747 shares. Acadia Pharmaceuticals Inc shares valued at $485,094 were divested by the CEO at a price of $15.28 per share. As a result of the transaction, DAVIS STEPHEN now holds 186,555 shares, worth roughly $2.75 million.
Morgan Stanley downgraded its Acadia Pharmaceuticals Inc [ACAD] rating to an Equal-weight from a an Overweight in a research note published on August 07, 2024; the price target was decreased to $20 from $28. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in late June with a ‘”an Outperform”‘ rating. Needham also remained covering ACAD and reiterated its “Buy” recommendation on March 12, 2024. Mizuho revised its rating on March 12, 2024. It rated ACAD as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ACAD
On Monday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock fall -2.45% to $14.73. Over the last five days, the stock has lost -4.23%. Acadia Pharmaceuticals Inc shares have fallen nearly -52.95% since the year began. Nevertheless, the stocks have fallen -32.92% over the past one year. While a 52-week high of $32.59 was reached on 01/02/24, a 52-week low of $14.55 was recorded on 06/10/24. SMA at 50 days reached $16.20, while 200 days put it at $19.43.
Levels Of Support And Resistance For ACAD Stock
The 24-hour chart illustrates a support level at 14.51, which if violated will result in even more drops to 14.28. On the upside, there is a resistance level at 15.05. A further resistance level may holdings at 15.36. The Relative Strength Index (RSI) on the 14-day chart is 36.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.74, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.12%. Stochastics %K at 11.31% indicates the stock is a buying.
How much short interest is there in Acadia Pharmaceuticals Inc?
A steep rise in short interest was recorded in Acadia Pharmaceuticals Inc stocks on 2024-09-13, dropping by -1.43 million shares to a total of 9.23 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 10.66 million shares. There was a decline of -15.48%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 30, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $40 price target.
